Boston Scientific (BSX) Misses Q4 EPS by 2c; Guides
Tweet
Share
E-mail
Get Alerts BSX Hot Sheet
Price: $47.80 +1.81%
EPS Growth %: +8.0%
Financial Fact:
Intangible asset impairment charges: 7M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +8.0%
Financial Fact:
Intangible asset impairment charges: 7M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Boston Scientific (NYSE: BSX) reported Q4 EPS of $0.45, $0.02 worse than the analyst estimate of $0.47. Revenue for the quarter came in at $3.24 billion versus the consensus estimate of $3.24 billion.
GUIDANCE:
Boston Scientific sees Q1 2023 EPS of $0.42-$0.44, versus the consensus of $0.44.
Boston Scientific sees FY2023 EPS of $1.86-$1.93, versus the consensus of $1.93.
For earnings history and earnings-related data on Boston Scientific (BSX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- JPMorgan Starts Bechtle AG (BC8:GR) (BECTY) at Neutral
- Ambarella (AMBA) Tops Q2 EPS by 1c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
